利巴韦林联合IFN治疗冠状病毒感染的研究进展

2019年底以来新型冠状病毒肺炎(新冠肺炎)席卷全球,病毒学分类委员会将新型冠状病毒命名为SARSCoV-2。目前对SARS-CoV-2知之甚少,尚未研发出针对该疾病的特效药物。但其与严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒同为β属冠状病毒,具有核苷酸同源性。既往严重急性呼吸综合征和中东呼吸综合征相关研究提示利巴韦林(ribavirin,RBV)联合IFN抗病毒治疗有效,为新冠肺炎的治疗提供了新的方向,但联合治疗的效果及安全性有待进一步临床试验证实。本文回顾总结了RBV联合IFN治疗冠状病毒感染的研究进展,以期为新冠肺炎的治疗提供参考。

Research progress of ribavirin combined with IFN in treatment of coronavirus infection

The novel coronavirus pneumonia has swept over the world since the end of 2019.The International Committee on Taxonomy of Viruses has named novel coronavirus as SARS-CoV-2.At present,little is known about SARS-CoV-2,and no specific drug has been developed for the disease.However,they are β-coronaviruses with the same nucleotide origin as severe acute respiratory syndrome coronavirus(SARS-CoV)and Middle East respiratory syndrome coronavirus(MERS-CoV).Previous studies on SARS and MERS suggest that ribavirin(RBV)combined with IFN is an effective antiviral therapy and provide a new direction for the treatment of novel coronavirus pneumonia.However,the efficacy and safety of the combined therapy need to be confirmed in further clinical trials.In this paper,research progress on the RBV+IFN in treatment of CoV infection is reviewed and summarized with expectations to provide reference for treating novel coronavirus pneumonia.